RT Journal Article SR Electronic T1 Detection of Synchronous Primary Malignancies with 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1938 OP 1942 DO 10.2967/jnumed.117.190215 VO 58 IS 12 A1 Medhat M. Osman A1 Amir Iravani A1 Rodney J. Hicks A1 Michael S. Hofman YR 2017 UL http://jnm.snmjournals.org/content/58/12/1938.abstract AB We evaluated the incidence of synchronous primary malignancies in patients undergoing 68Ga-labeled prostate-specific membrane antigen PET/CT for prostate cancer (PC). Methods: Reports for 764 PC patients were reviewed. Incidental lesions atypical for PC metastases and suggestive of a synchronous primary malignancy were identified. Follow-up was obtained to confirm etiology. Results: Lesions atypical for PC metastases were found in 49 (6.4%) of 764 patients, and a synchronous primary malignancy was confirmed in 5 patients (0.7%; 2 lung, 1 lymphoma, 1 thyroid, and 1 base of tongue). In 8 patients (1.0%), lesions were proven to be atypical metastases from PC. In 24 patients (3.1%), lesions had a benign etiology. Follow-up was not available in 12 patients (1.6%). Conclusion: Synchronous 68Ga-labeled prostate-specific membrane antigen–avid malignancies were rare (0.7%) in PC patients; atypical lesions were more commonly unusual PC metastases (1.0%) or benign (3.1%).